Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent

Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent

Wei Liu,1,* Jin-Feng Ning,2,* Qing-Wei Meng,1 Jing Hu,1 Yan-Bin Zhao,1 Chao Liu,3 Li Cai11The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, 2The Thoracic Surgery Department, Harbin Medical University Cancer Hospital, Harbin, People’s Republic of China; 3...

Full description

Bibliographic Details
Main Authors:	Liu W, Ning JF, Meng QW, Hu J, Zhao YB, Liu C, Cai L
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-07-01
Series:	Drug Design, Development and Therapy
Online Access:	http://www.dovepress.com/navigating-into-the-binding-pockets-of-the-her-family-protein-kinases--peer-reviewed-article-DDDT

Similar Items

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model
by: Collantes Maria, et al.
Published: (2010-05-01)

Pockets as structural descriptors of EGFR kinase conformations.
by: Marcia Anahi Hasenahuer, et al.
Published: (2017-01-01)

Discovery of Novel EGFR Kinase Inhibitors as Anticancer Agents
by: Wu, Chia-Hsien, et al.
Published: (2010)

Correction: Pockets as structural descriptors of EGFR kinase conformations.
by: Marcia Anahi Hasenahuer, et al.
Published: (2018-01-01)

Design and Discovery of 3rd Generation EGFR Tyrosine Kinase Inhibitors
by: Hsueh, Chin, et al.
Published: (2018)

Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.
by: Hwang-Phill Kim, et al.
Published: (2009-01-01)

The Role of Cigarette Smoke-Derived Carcinogens in Influencing the Antitumor Activity of EGFR Tyrosine Kinase Inhibitors
by: Shu-Lin Wang, et al.
Published: (2013)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
by: Cornelius Hempel, et al.
Published: (2017-01-01)

Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors
by: Yuanbiao Tu, et al.
Published: (2018-01-01)

Laboratory and clinical studies of the dual EGFR/HER2 tyrosine kinase inhibitor lapatinib in breast cancer
by: Leary, Alexandra
Published: (2011)

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
by: Anthony Kong, et al.
Published: (2008-08-01)

Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors.
by: Floriana Morgillo, et al.
Published: (2011-01-01)

Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
by: Yun Jung Choi, et al.
Published: (2013-01-01)

Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
by: Dong-Dong Li, et al.
Published: (2013-01-01)

Modulation of DNA strand break induction and repair by tyrosine kinase inhibitors targeted against EGFR and HER2
by: Bhosle, J.
Published: (2012)

Activation of HER3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors: Suggestion of Combination Therapy
by: Robert Torka, et al.
Published: (2014-04-01)

EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells
by: Nina Mallmann-Gottschalk, et al.
Published: (2019-09-01)

Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.
by: Shigeki Nanjo, et al.
Published: (2013-01-01)

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors.
by: Yun Jung Choi, et al.
Published: (2019-01-01)

Indirect and Direct Drug Design of EGFR and HER2 Inhibitors
by: Ting-Yu Chang, et al.
Published: (2013)

Pim kinase inhibitors possess anticancer properties through downregulation of EGFR family in HER2-positive cancer cells
by: Yu-Fei Wang, et al.
Published: (2015)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015-09-01)

Design and Synthesis of Novel EGFR Kinase Inhibitors
by: Liang, Keng-Fu, et al.
Published: (2011)

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
by: Wang X, et al.
Published: (2016-09-01)

Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors.
by: PLOS ONE Editors
Published: (2019-01-01)

BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer
by: Fushun Fan, et al.
Published: (2021-02-01)

Discovery of Potent EGFR Inhibitors With 6-Arylureido-4-anilinoquinazoline Derivatives
by: Meng Li, et al.
Published: (2021-05-01)

Discovery and antitumor evaluation of novel inhibitors of spermine oxidase
by: Lidan Sun, et al.
Published: (2019-01-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
by: Tim Fischer, et al.
Published: (2018-01-01)

Efficient Molecular Docking for Hit Discovery on EGFR Tyrosine Kinase Inhibitors of Non-Small Cell Lung Cancer
by: Wei-Chen Lin, et al.
Published: (2017)

The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
by: Xiaofei Chang, et al.
Published: (2013-01-01)

Design, synthesis and in vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment
by: Yi Le, et al.
Published: (2020-01-01)

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
by: Donatella Romaniello, et al.
Published: (2020-08-01)

Sensitivity of EGFR/HER-2 Positive Cells Isolated from Ascitic Fluid of Advanced Ovarian Cancer Patients to EGFR/HER-2 Inhibitors
by: Kenny Chitcholtan, et al.
Published: (2020-03-01)

PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations
by: Qiuju Dong, et al.
Published: (2019-04-01)

Structural and functional insights into the HIV-1 maturation inhibitor binding pocket.
by: Kayoko Waki, et al.
Published: (2012-01-01)

Discovery of Potent Dual EGFR/HER2 Inhibitors Based on Thiophene Scaffold Targeting H1299 Lung Cancer Cell Line
by: Ranza Elrayess, et al.
Published: (2021-12-01)

Discovery of stimulator binding to a conserved pocket in the heme domain of soluble guanylyl cyclase
by: Wales, Jessica A., et al.
Published: (2018)

De Novo HER2 S310Y mutation associates with poor response to EGFR tyrosine kinase inhibitor in activating EGFR-mutant NSCLC patient: A case report
by: Fei Gao, et al.
Published: (2019-02-01)

Discovery of aminopyridine-containing spiro derivatives as EGFR mutations inhibitors
by: Lianbao Ye, et al.
Published: (2019-01-01)

Cannot write session to /tmp/vufind_sessions/sess_5riuejv6gnj0es9kguqsc2ovnk